-
Safety and Efficacy of Para-Aminohippurate Coinfusion for Renal Protection During Peptide Receptor Radiotherapy in Patients with Neuroendocrine Tumors J Nucl. Med. (IF 9.3) Pub Date : 2024-04-18 Alexandros Moraitis, Walter Jentzen, Pedro Fragoso Costa, David Kersting, Stephan Himmen, Marta Coelho, Marian Meckel, Cees J.A. van Echteld, Wolfgang P. Fendler, Ken Herrmann, Miriam Sraieb
Visual Abstract
-
A Deep-Learning–Based Partial-Volume Correction Method for Quantitative 177Lu SPECT/CT Imaging J Nucl. Med. (IF 9.3) Pub Date : 2024-04-18 Julian Leube, Johan Gustafsson, Michael Lassmann, Maikol Salas-Ramirez, Johannes Tran-Gia
Visual Abstract
-
Detecting Metastatic Patterns of Oligometastatic Breast Cancer: A Comparative Analysis of 18F-FDG PET/CT and Conventional CT Imaging J Nucl. Med. (IF 9.3) Pub Date : 2024-04-18 Rebecca Moser, Sophie Pfeiffer, Lisena Cala, Evelyn Klein, Marion Kiechle, Sophie T. Behzadi, Eva Fallenberg, Stephanie E. Combs, Wolfgang Weber, Kai J. Borm
Visual Abstract
-
RECIP 1.0 Predicts Progression-Free Survival After [177Lu]Lu-PSMA Radiopharmaceutical Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer J Nucl. Med. (IF 9.3) Pub Date : 2024-04-18 Andrei Gafita, Loic Djaileb, Isabel Rauscher, Wolfgang P. Fendler, Boris Hadaschik, Steven P. Rowe, Ken Herrmann, Lilja B. Solnes, Jeremie Calais, Matthew B. Rettig, Manuel Weber, Andrea Farolfi, Matthias R. Benz, Matthias Eiber
Visual Abstract
-
A Systematic Review on the Diagnostic Value of Fibroblast Activation Protein Inhibitor PET/CT in Genitourinary Cancers J Nucl. Med. (IF 9.3) Pub Date : 2024-04-18 Marinus J. Hagens, Pim J. van Leeuwen, Maurits Wondergem, Thierry N. Boellaard, Francesco Sanguedolce, Daniela E. Oprea-Lager, Axel Bex, André N. Vis, Henk G. van der Poel, Laura S. Mertens, in collaboration with the EAU Section of Urological Imaging
Visual Abstract
-
Absorbed Dose–Response Relationship in Patients with Gastroenteropancreatic Neuroendocrine Tumors Treated with [177Lu]Lu-DOTATATE: One Step Closer to Personalized Medicine J Nucl. Med. (IF 9.3) Pub Date : 2024-04-18 Kévin Hebert, Lore Santoro, Maeva Monnier, Florence Castan, Ikrame Berkane, Eric Assénat, Cyril Fersing, Pauline Gélibert, Jean-Pierre Pouget, Manuel Bardiès, Pierre-Olivier Kotzki, Emmanuel Deshayes
Visual Abstract
-
Development of a Visually Calculated SUVmean (HIT Score) on Screening PSMA PET/CT to Predict Treatment Response to 177Lu-PSMA Therapy: Comparison with Quantitative SUVmean and Patient Outcomes J Nucl. Med. (IF 9.3) Pub Date : 2024-04-18 Mina Swiha, Nathan Papa, Zahra Sabahi, Narjess Ayati, Nikeith John, Sarennya Pathmanandavel, Megan Crumbaker, Sherrington Li, Shikha Agrawal, Maria Ayers, Adam Hickey, Shikha Sharma, Andrew Nguyen, Louise Emmett
Visual Abstract
-
Mapping 18F-FDG Kinetics Together with Patient-Specific Bootstrap Assessment of Uncertainties: An Illustration with Data from a PET/CT Scanner with a Long Axial Field of View J Nucl. Med. (IF 9.3) Pub Date : 2024-04-11 Qi Wu, Fengyun Gu, Liam D. O’Suilleabhain, Hasan Sari, Song Xue, Kuangyu Shi, Axel Rominger, Finbarr O’Sullivan
Visual Abstract
-
PET Quantification of [18F]VAT in Human Brain and Its Test–Retest Reproducibility and Age Dependence J Nucl. Med. (IF 9.3) Pub Date : 2024-04-11 John L. O’Donnell, Anil Kumar Soda, Hao Jiang, Scott A. Norris, Baijayanta Maiti, Morvarid Karimi, Meghan C. Campbell, Stephen M. Moerlein, Zhude Tu, Joel S. Perlmutter
Visual Abstract
-
68Ga-NC-BCH Whole-Body PET Imaging Rapidly Targets Claudin18.2 in Lesions in Gastrointestinal Cancer Patients J Nucl. Med. (IF 9.3) Pub Date : 2024-04-11 Changsong Qi, Rui Guo, Yan Chen, Chenzhen Li, Chang Liu, Miao Zhang, Cheng Zhang, Xiaotian Zhang, Xingguo Hou, Bo Chen, Bing Jia, Zhi Yang, Lin Shen, Hua Zhu
Visual Abstract
-
Clinical Management of Advanced Prostate Cancer: Where Does Radiopharmaceutical Therapy Fit in the Treatment Algorithm? J Nucl. Med. (IF 9.3) Pub Date : 2024-04-11 Paul Viscuse, Michael Devitt, Robert Dreicer
Most men with newly appreciated metastatic prostate cancer are optimally treated with a backbone consisting of androgen receptor–directed therapy with or without taxane chemotherapy. Despite improvements in disease outcomes, prostate cancer remains an extremely heterogeneous disease with variable mechanisms of therapeutic resistance. As a result, it remains a leading cause of cancer-related death in
-
Diagnostic Potential of Supplemental Static and Dynamic 68Ga-FAPI-46 PET for Primary 18F-FDG–Negative Pulmonary Lesions J Nucl. Med. (IF 9.3) Pub Date : 2024-04-11 Manuel Röhrich, Johanna Daum, Ewgenija Gutjahr, Anna-Maria Spektor, Frederik M. Glatting, Yasemin Aylin Sahin, Hans Georg Buchholz, Jorge Hoppner, Cathrin Schroeter, Eleni Mavriopoulou, Kai Schlamp, Matthias Grott, Florian Eichhorn, Claus Peter Heußel, Hans Ulrich Kauczor, Michael Kreuter, Frederik Giesel, Mathias Schreckenberger, Hauke Winter, Uwe Haberkorn
Visual Abstract
-
Improved Tau PET SUVR Quantification in 4-Repeat Tau Phenotypes with [18F]PI-2620 J Nucl. Med. (IF 9.3) Pub Date : 2024-04-04 Gérard N. Bischof, Matthias Brendel, Henryk Barthel, Hendrik Theis, Michael Barbe, Peter Bartenstein, Joseph Claasen, Adrian Danek, Günter Höglinger, Johannes Levin, Ken Marek, Bernd Neumaier, Carla Palleis, Marianne Patt, Michael Rullmann, Dorothee Saur, Matthias L. Schroeter, John Seibyl, Mengmeng Song, Andrew Stephens, Osama Sabri, Alexander Drzezga, Thilo van Eimeren, for the German Imaging Initiative
Visual Abstract
-
Optimal [18F]FDG PET/CT Cutoff for Pathologic Complete Response in HER2-Positive Early Breast Cancer Patients Treated with Neoadjuvant Trastuzumab and Pertuzumab in the PHERGain Trial J Nucl. Med. (IF 9.3) Pub Date : 2024-04-04 Geraldine Gebhart, Marleen Keyaerts, Thomas Guiot, Patrick Flamen, Manuel Ruiz-Borrego, Agostina Stradella, Begoña Bermejo, Santiago Escriva-de-Romani, Lourdes Calvo Martínez, Nuria Ribelles, María Fernandez-Abad, Cinta Albacar, Marco Colleoni, Laia Garrigos, Manuel Atienza de Frutos, Florence Dalenc, Aleix Prat, Frederik Marmé, Peter Schmid, Khaldoun Kerrou, Sofia Braga, Petra Gener, Miguel Sampayo-Cordero
Visual Abstract
-
Detecting High-Dose Methotrexate–Induced Brain Changes in Pediatric and Young Adult Cancer Survivors Using [18F]FDG PET/MRI: A Pilot Study J Nucl. Med. (IF 9.3) Pub Date : 2024-04-04 Lucia Baratto, Shashi B. Singh, Sharon E. Williams, Sheri L. Spunt, Jarrett Rosenberg, Lisa Adams, Vidyani Suryadevara, Michael Iv, Heike Daldrup-Link
Visual Abstract
-
Impact of PET Reconstruction on Amyloid-{beta} Quantitation in Cross-Sectional and Longitudinal Analyses J Nucl. Med. (IF 9.3) Pub Date : 2024-04-04 Ruwanpathirana, G. P., Williams, R. C., Masters, C. L., Rowe, C. C., Johnston, L. A., Davey, C. E.
Visual Abstract
-
ISIT-QA: In Silico Imaging Trial to Evaluate a Low-Count Quantitative SPECT Method Across Multiple Scanner–Collimator Configurations for 223Ra-Based Radiopharmaceutical Therapies J Nucl. Med. (IF 9.3) Pub Date : 2024-04-04 Zekun Li, Nadia Benabdallah, Jingqin Luo, Richard L. Wahl, Daniel L.J. Thorek, Abhinav K. Jha
Visual Abstract
-
Early Metabolic Response by PET Predicts Sensitivity to Next-Line Targeted Therapy in EGFR-Mutated Lung Cancer with Unknown Mechanism of Acquired Resistance J Nucl. Med. (IF 9.3) Pub Date : 2024-04-04 Martin Schuler, Jörg Hense, Kaid Darwiche, Sebastian Michels, Hubertus Hautzel, Carsten Kobe, Smiths Lueong, Martin Metzenmacher, Thomas Herold, Gregor Zaun, Katharina Laue, Alexander Drzezga, Dirk Theegarten, Felix Nensa, Jürgen Wolf, Ken Herrmann, Marcel Wiesweg
Visual Abstract
-
The Accomplishments and Legacy of Saul Hertz, MD J Nucl. Med. (IF 9.3) Pub Date : 2024-04-01 Bennett S. Greenspan, Michael S. Hofman, John Buscombe
The early history of the use of radioactive iodine (RAI) is complicated and interesting, and also difficult to discover, especially since several histories have presented inaccurate content. This article is a comprehensive review of the accomplishments of Saul Hertz. Extensive use of primary-source verification has clarified several issues, including the question of whether Hertz alone conceived and
-
Performance Evaluation of the uMI Panorama PET/CT System in Accordance with the National Electrical Manufacturers Association NU 2-2018 Standard J Nucl. Med. (IF 9.3) Pub Date : 2024-04-01 Guiyu Li, Wenhui Ma, Xiang Li, Weidong Yang, Zhiyong Quan, Taoqi Ma, Junling Wang, Yunya Wang, Fei Kang, Jing Wang
The uMI Panorama is a novel PET/CT system using silicon photomultiplier and application-specific integrated circuit technologies and providing exceptional spatial and time-of-flight (TOF) resolutions. The objective of this study was to assess the physical performance of the uMI Panorama in accordance with the National Electrical Manufacturers Association (NEMA) NU 2-2018 standard. Methods: Spatial
-
Deep Semisupervised Transfer Learning for Fully Automated Whole-Body Tumor Quantification and Prognosis of Cancer on PET/CT J Nucl. Med. (IF 9.3) Pub Date : 2024-04-01 Leung, K. H., Rowe, S. P., Sadaghiani, M. S., Leal, J. P., Mena, E., Choyke, P. L., Du, Y., Pomper, M. G.
Automatic detection and characterization of cancer are important clinical needs to optimize early treatment. We developed a deep, semisupervised transfer learning approach for fully automated, whole-body tumor segmentation and prognosis on PET/CT. Methods: This retrospective study consisted of 611 18F-FDG PET/CT scans of patients with lung cancer, melanoma, lymphoma, head and neck cancer, and breast
-
Promising Candidate Prognostic Biomarkers in [18F]FDG PET Images: Evaluation in Independent Cohorts of Non–Small Cell Lung Cancer Patients J Nucl. Med. (IF 9.3) Pub Date : 2024-04-01 Narinée Hovhannisyan-Baghdasarian, Marie Luporsi, Nicolas Captier, Christophe Nioche, Vesna Cuplov, Erwin Woff, Nadia Hegarat, Alain Livartowski, Nicolas Girard, Irène Buvat, Fanny Orlhac
The normalized distances from the hot spot of radiotracer uptake (SUVmax) to the tumor centroid (NHOC) and to the tumor perimeter (NHOP) have recently been suggested as novel PET features reflecting tumor aggressiveness. These biomarkers characterizing the shift of SUVmax toward the lesion edge during tumor progression have been shown to be prognostic factors in breast and non–small cell lung cancer
-
PET/CT-Based Radiogenomics Supports KEAP1/NFE2L2 Pathway Targeting for Non–Small Cell Lung Cancer Treated with Curative Radiotherapy J Nucl. Med. (IF 9.3) Pub Date : 2024-04-01 Vincent Bourbonne, Moncef Morjani, Olivier Pradier, Mathieu Hatt, Vincent Jaouen, Solène Querellou, Dimitris Visvikis, François Lucia, Ulrike Schick
In lung cancer patients, radiotherapy is associated with a increased risk of local relapse (LR) when compared with surgery but with a preferable toxicity profile. The KEAP1/NFE2L2 mutational status (MutKEAP1/NFE2L2) is significantly correlated with LR in patients treated with radiotherapy but is rarely available. Prediction of MutKEAP1/NFE2L2 with noninvasive modalities could help to further personalize
-
Clinical Evaluation of Deep Learning for Tumor Delineation on 18F-FDG PET/CT of Head and Neck Cancer J Nucl. Med. (IF 9.3) Pub Date : 2024-04-01 David G. Kovacs, Claes N. Ladefoged, Kim F. Andersen, Jane M. Brittain, Charlotte B. Christensen, Danijela Dejanovic, Naja L. Hansen, Annika Loft, Jørgen H. Petersen, Michala Reichkendler, Flemming L. Andersen, Barbara M. Fischer
Artificial intelligence (AI) may decrease 18F-FDG PET/CT–based gross tumor volume (GTV) delineation variability and automate tumor-volume–derived image biomarker extraction. Hence, we aimed to identify and evaluate promising state-of-the-art deep learning methods for head and neck cancer (HNC) PET GTV delineation. Methods: We trained and evaluated deep learning methods using retrospectively included
-
[18F]FDG PET/CT Signal Correlates with Neoangiogenesis Markers in Patients with Fibrotic Interstitial Lung Disease Who Underwent Lung Biopsy: Implication for the Use of PET/CT in Diffuse Lung Diseases J Nucl. Med. (IF 9.3) Pub Date : 2024-04-01 Joanna C. Porter, Balaji Ganeshan, Thida Win, Francesco Fraioli, Saif Khan, Manuel Rodriguez-Justo, Raymond Endozo, Robert I. Shortman, Luke R. Hoy, Toby M. Maher, Ashley M. Groves
The use of [18F]FDG PET/CT as a biomarker in diffuse lung diseases is increasingly recognized. We investigated the correlation between [18F]FDG uptake with histologic markers on lung biopsy of patients with fibrotic interstitial lung disease (fILD). Methods: We recruited 18 patients with fILD awaiting lung biopsy for [18F]FDG PET/CT. We derived a target-to-background ratio (TBR) of maximum pulmonary
-
Total-Body PET/CT Applications in Cardiovascular Diseases: A Perspective Document of the SNMMI Cardiovascular Council J Nucl. Med. (IF 9.3) Pub Date : 2024-04-01 Riemer H.J.A. Slart, Frank M. Bengel, Cigdem Akincioglu, Jamieson M. Bourque, Wengen Chen, Marc R. Dweck, Marcus Hacker, Saurabh Malhotra, Edward J. Miller, Matthieu Pelletier-Galarneau, René R.S. Packard, Thomas H. Schindler, Richard L. Weinberg, Antti Saraste, Piotr J. Slomka
Digital PET/CT systems with a long axial field of view have become available and are emerging as the current state of the art. These new camera systems provide wider anatomic coverage, leading to major increases in system sensitivity. Preliminary results have demonstrated improvements in image quality and quantification, as well as substantial advantages in tracer kinetic modeling from dynamic imaging
-
Can Internal Carotid Arteries Be Used for Noninvasive Quantification of Brain PET Studies? J Nucl. Med. (IF 9.3) Pub Date : 2024-04-01 Laura Providência, Chris W.J. van der Weijden, Philipp Mohr, Joyce van Sluis, Johannes H. van Snick, Riemer H.J.A. Slart, Rudi A.J.O. Dierckx, Adriaan A. Lammertsma, Charalampos Tsoumpas
Because of the limited axial field of view of conventional PET scanners, the internal carotid arteries are commonly used to obtain an image-derived input function (IDIF) in quantitative brain PET. However, time–activity curves extracted from the internal carotids are prone to partial-volume effects due to the limited PET resolution. This study aimed to assess the use of the internal carotids for quantifying
-
Development and Preclinical Evaluation of [211At]PSAt-3-Ga: An Inhibitor for Targeted {alpha}-Therapy of Prostate Cancer J Nucl. Med. (IF 9.3) Pub Date : 2024-04-01 El Fakiri, M., Ayada, N., Muller, M., Hvass, L., Gamzov, T. H., Clausen, A. S., Geis, N. M., Steinacker, N., Hansson, E., Lindegren, S., Aneheim, E., Jensen, H., Eder, A.-C., Jensen, A. I., Poulie, C. B. M., Kjaer, A., Eder, M., Herth, M. M.
The application of prostate-specific membrane antigen (PSMA)–targeted α-therapy is a promising alternative to β–-particle–based treatments. 211At is among the potential α-emitters that are favorable for this concept. Herein, 211At-based PSMA radiopharmaceuticals were designed, developed, and evaluated. Methods: To identify a 211At-labeled lead, a surrogate strategy was applied. Because astatine does
-
Peptide Binder to Glypican-3 as a Theranostic Agent for Hepatocellular Carcinoma J Nucl. Med. (IF 9.3) Pub Date : 2024-04-01 Lin, F., Clift, R., Ehara, T., Yanagida, H., Horton, S., Noncovich, A., Guest, M., Kim, D., Salvador, K., Richardson, S., Miller, T., Han, G., Bhat, A., Song, K., Li, G.
Glypican-3 (GPC3) is a membrane-associated glycoprotein that is significantly upregulated in hepatocellular carcinomas (HCC) with minimal to no expression in normal tissues. The differential expression of GPC3 between tumor and normal tissues provides an opportunity for targeted radiopharmaceutical therapy to treat HCC, a leading cause of cancer-related deaths worldwide. Methods: DOTA-RYZ-GPC3 (RAYZ-8009)
-
Interrogating the Theranostic Capacity of a MUC16-Targeted Antibody for Ovarian Cancer J Nucl. Med. (IF 9.3) Pub Date : 2024-04-01 Mack, K. N., Samuels, Z. V., Carter, L. M., Viray, T. D., Mandleywala, K., Brooks, C. L., Hollingsworth, M. A., Radhakrishnan, P., Lewis, J. S.
Aberrantly expressed glycans on mucins such as mucin-16 (MUC16) are implicated in the biology that promotes ovarian cancer (OC) malignancy. Here, we investigated the theranostic potential of a humanized antibody, huAR9.6, targeting fully glycosylated and hypoglycosylated MUC16 isoforms. Methods: In vitro and in vivo targeting of the diagnostic radiotracer [89Zr]Zr-DFO-huAR9.6 was investigated via binding
-
Radiolabeled Somatostatin Receptor Antagonist Versus Agonist for Peptide Receptor Radionuclide Therapy in Patients with Therapy-Resistant Meningioma: PROMENADE Phase 0 Study J Nucl. Med. (IF 9.3) Pub Date : 2024-04-01 Eigler, C., McDougall, L., Bauman, A., Bernhardt, P., Hentschel, M., Blackham, K. A., Nicolas, G., Fani, M., Wild, D., Cordier, D.
Our primary aim was to compare the therapeutic index (tumor–to–bone marrow and tumor-to-kidney absorbed-dose ratios) of the new radiolabeled somatostatin receptor antagonist [177Lu]Lu-DOTA-JR11 with the established radiolabeled somatostatin receptor agonist [177Lu]Lu-DOTATOC in the same patients with progressive, standard therapy-refractory meningioma. Methods: In this prospective, single-center, open-label
-
Single-Time-Point Renal Dosimetry Using Nonlinear Mixed-Effects Modeling and Population-Based Model Selection in [177Lu]Lu-PSMA-617 Therapy J Nucl. Med. (IF 9.3) Pub Date : 2024-04-01 Deni Hardiansyah, Elham Yousefzadeh-Nowshahr, Felix Kind, Ambros J. Beer, Juri Ruf, Gerhard Glatting, Michael Mix
The aim of this study was to investigate the accuracy of single-time-point (STP) renal dosimetry imaging using SPECT/CT data, a nonlinear mixed-effects (NLME) model, and a population-based model selection (PBMS) in a large population for 177Lu-labeled prostate-specific membrane antigen therapy. Methods: Biokinetic data (mean ± SD) of [177Lu]Lu-PSMA-617 in kidneys at time points 1 (1.8 ± 0.8 h), 2 (18
-
Prognostic Performance of RECIP 1.0 Based on [18F]PSMA-1007 PET in Prostate Cancer Patients Treated with [177Lu]Lu-PSMA I&T J Nucl. Med. (IF 9.3) Pub Date : 2024-04-01 Philipp E. Hartrampf, Thomas Hüttmann, Anna Katharina Seitz, Hubert Kübler, Sebastian E. Serfling, Takahiro Higuchi, Wiebke Schlötelburg, Kerstin Michalski, Andrei Gafita, Steven P. Rowe, Martin G. Pomper, Andreas K. Buck, Rudolf A. Werner
In metastatic castration-resistant prostate cancer (mCRPC) patients treated with prostate-specific membrane antigen (PSMA)–targeted radioligand therapy (RLT), the recently proposed criteria for evaluating response to PSMA PET (RECIP 1.0) based on 68Ga- and 18F-labeled PET agents provided prognostic information in addition to changes in prostate-specific antigen (PSA) levels. Our aim was to evaluate
-
The Value of 68Ga-PSMA PET/MRI for Classifying Patients with PI-RADS 3 Lesions on Multiparametric MRI: A Prospective Single-Center Study J Nucl. Med. (IF 9.3) Pub Date : 2024-04-01 Shi, J., Li, D., Chen, M., Fu, Y., Peng, S., Zhang, Q., Liang, J., Lu, Q., Lu, J., Ai, S., Wang, F., Qiu, X., Guo, H.
Prostate Imaging Reporting and Data System (PI-RADS) category 3 lesions remain a diagnostic challenge for detecting clinically significant prostate cancer (csPCa). This article evaluates the added value of 68Ga-labeled prostate-specific membrane antigen-11 (68Ga-PSMA) PET/MRI in classifying PI-RADS 3 lesions to avoid unnecessary biopsies. Methods: Sixty biopsy-naïve men with PI-RADS 3 lesions on multiparametric
-
Strong Correlation Between SUVmax on PSMA PET/CT and Numeric Drop-In {gamma}-Probe Signal for Intraoperative Identification of Prostate Cancer Lesions J Nucl. Med. (IF 9.3) Pub Date : 2024-04-01 Berrens, A.-C., Sorbi, M. A., Donswijk, M. L., de Barros, H. A., Azargoshasb, S., van Oosterom, M. N., Rietbergen, D. D. D., Bekers, E. M., van der Poel, H. G., van Leeuwen, F. W. B., van Leeuwen, P. J.
Prostate-specific membrane antigen (PSMA) PET is used to select patients with recurrent prostate cancer for metastasis-directed therapy. A surgical approach can be achieved through radioguided surgery (RGS), using a Drop-In -probe that traces lesions that accumulate the radioactive signal. With the aim of guiding patient selection for salvage surgery, we studied the correlation between the SUVmax of
-
The Impact of Baseline PSMA PET/CT Versus CT on Outcomes of 223Ra Therapy in Metastatic Castration-Resistant Prostate Cancer Patients J Nucl. Med. (IF 9.3) Pub Date : 2024-04-01 Bosch, D., van der Velden, K. J. M., Oving, I. M., Wyndaele, D. N. J., Weijs, L. E., van Schelven, W. D., Oyen, W. J. G., te Beek, E. T., van de Luijtgaarden, A. C. M., Somford, D. M., Nagarajah, J., Hermsen, R., Mehra, N., Gerritsen, W. R., van der Doelen, M. J., van Oort, I. M.
Imaging before 223Ra-dichloride (223Ra) therapy is crucial for selecting metastatic castration-resistant prostate cancer (mCRPC) patients with bone-only disease. The purpose of this study was to evaluate if baseline prostate-specific membrane antigen (PSMA) PET/CT (bPSMA) versus CT is associated with outcomes of 223Ra therapy. Methods: A secondary analysis of the data of a prospective observational
-
Efficacy of [67Cu]Cu-EB-TATE Theranostic Against Somatostatin Receptor Subtype-2-Positive Neuroendocrine Tumors J Nucl. Med. (IF 9.3) Pub Date : 2024-04-01 Njotu, F. N., Ketchemen, J. P., Tikum, A. F., Babeker, H., Gray, B. D., Pak, K. Y., Uppalapati, M., Fonge, H.
β–-emitting 177Lu-octreotate is an approved somatostatin receptor subtype 2 (SSTR2)–directed peptide receptor radionuclide therapy for the treatment of gastroenteropancreatic neuroendocrine tumors (NETs). However,177Lu-octreotate has fast pharmacokinetics, requiring up to 4 treatment doses. Moreover, 177Lu is less than ideal for theranostics because of the low branching ratio of its -emissions, which
-
68Ga-FAPI-04 PET/CT in Non–Small Cell Lung Cancer: Accurate Evaluation of Lymph Node Metastasis and Correlation with Fibroblast Activation Protein Expression J Nucl. Med. (IF 9.3) Pub Date : 2024-04-01 Chongjiao Li, Qiongrong Chen, Yueli Tian, Jie Chen, Kui Xu, Zhiwei Xiao, Juan Zhong, Jianyuan Wu, Bing Wen, Yong He
Fibroblast activation protein (FAP) is a promising diagnostic and therapeutic target in various solid tumors. This study aimed to assess the diagnostic efficiency of 68Ga-labeled FAP inhibitor (FAPI)–04 PET/CT for detecting lymph node metastasis in non–small cell lung cancer (NSCLC) and to investigate the correlation between tumor 68Ga-FAPI-04 uptake and FAP expression. Methods: We retrospectively
-
An 18F-FDG PET/CT and Mean Lung Dose Model to Predict Early Radiation Pneumonitis in Stage III Non–Small Cell Lung Cancer Patients Treated with Chemoradiation and Immunotherapy J Nucl. Med. (IF 9.3) Pub Date : 2024-04-01 Maria Thor, Chen Lee, Lian Sun, Purvi Patel, Aditya Apte, Milan Grkovski, Annemarie F. Shepherd, Daphna Y. Gelblum, Abraham J. Wu, Charles B. Simone, Jamie E. Chaft, Andreas Rimner, Daniel R. Gomez, Joseph O. Deasy, Narek Shaverdian
Radiation pneumonitis (RP) that develops early (i.e., within 3 mo) (RPEarly) after completion of concurrent chemoradiation (cCRT) leads to treatment discontinuation and poorer survival for patients with stage III non–small cell lung cancer. Since no RPEarly risk model exists, we explored whether published RP models and pretreatment 18F-FDG PET/CT–derived features predict RPEarly. Methods: One hundred
-
68Ga-FAPI PET/CT as an Alternative to 18F-FDG PET/CT in the Imaging of Invasive Lobular Breast Carcinoma J Nucl. Med. (IF 9.3) Pub Date : 2024-04-01 Ertan Sahin, Tulay Kus, Alper Aytekin, Evren Uzun, Umut Elboga, Latif Yilmaz, Yusuf B. Cayirli, Merve Okuyan, Vuslat Cimen, Ufuk Cimen
Accurate staging of invasive lobular carcinoma (ILC), a subtype of breast cancer, is vital for effective clinical management. Although 18F-FDG PET/CT is a commonly used tool, its efficacy varies across different histologic subtypes. To mitigate this challenge, our investigation delves into the potential utility of 68Ga-fibroblast activation protein inhibitor (FAPI) PET/CT as an alternative for staging
-
The Potential Contribution of Radiopharmaceutical Therapies in Managing Oligometastatic Disease J Nucl. Med. (IF 9.3) Pub Date : 2024-04-01 Kishan, A. U., Siva, S., Hofman, M. S., Nagarajah, J., Kiess, A. P., Tran, P., Calais, J.
There is a growing understanding of the oligometastatic disease state, characterized by the presence of 5 or fewer lesions. Advanced molecular imaging techniques, such as prostate-specific membrane antigen PET, refines the ability to detect oligometastatic recurrences (oligorecurrences) early. These developments have led to the exploration of metastasis-directed therapy (MDT) in oligorecurrent disease
-
SPECT/CT Image-Derived Absorbed Dose to Red Marrow Correlates with Hematologic Toxicity in Patients Treated with [177Lu]Lu-DOTATATE J Nucl. Med. (IF 9.3) Pub Date : 2024-03-28 Johan Blakkisrud, Avery B. Peterson, Scott J. Wildermann, Griffen Kingkiner, Ka Kit Wong, Chang Wang, Kirk A. Frey, Caroline Stokke, Yuni K. Dewaraja
Visual Abstract
-
Artificial Intelligence Predicts Hospitalization for Acute Heart Failure Exacerbation in Patients Undergoing Myocardial Perfusion Imaging J Nucl. Med. (IF 9.3) Pub Date : 2024-03-28 Feher, A., Bednarski, B., Miller, R. J., Shanbhag, A., Lemley, M., Miras, L., Sinusas, A. J., Miller, E. J., Slomka, P. J.
Visual Abstract
-
Cancer Risk in Graves Disease with Radioactive 131I Treatment: A Nationwide Cohort Study J Nucl. Med. (IF 9.3) Pub Date : 2024-03-28 Kyeong Jin Kim, Jimi Choi, Kyoung Jin Kim, Eyun Song, Ji Hee Yu, Nam Hoon Kim, Hye Jin Yoo, Ji A Seo, Nan Hee Kim, Kyung Mook Choi, Sei Hyun Baik, Sin Gon Kim
Visual Abstract
-
Development of a CD163-Targeted PET Radiotracer That Images Resident Macrophages in Atherosclerosis J Nucl. Med. (IF 9.3) Pub Date : 2024-03-28 Xiuli Zhang, Gyu Seong Heo, Alexandria Li, Divangana Lahad, Lisa Detering, Joan Tao, Xuefeng Gao, Xiaohui Zhang, Hannah Luehmann, Deborah Sultan, Lanlan Lou, Rajiu Venkatesan, Ran Li, Jie Zheng, Junedh Amrute, Chieh-Yu Lin, Benjamin J. Kopecky, Robert J. Gropler, Andrea Bredemeyer, Kory Lavine, Yongjian Liu
Visual Abstract
-
Human Epidermal Growth Factor Receptor 2 (HER2) PET Imaging of HER2-Low Breast Cancer with [68Ga]Ga-ABY-025: Results from a Pilot Study J Nucl. Med. (IF 9.3) Pub Date : 2024-03-28 Altena, R., Buren, S. a., Blomgren, A., Karlsson, E., Tzortzakakis, A., Brun, N., Moein, M. M., Jussing, E., Frejd, F. Y., Bergh, J., Tran, T. A., Hartman, J., Axelsson, R.
Visual Abstract
-
Is PET Radiomics Useful to Predict Pathologic Tumor Response and Prognosis in Locally Advanced Cervical Cancer? J Nucl. Med. (IF 9.3) Pub Date : 2024-03-28 Angela Collarino, Vanessa Feudo, Tina Pasciuto, Anita Florit, Elisabeth Pfaehler, Marco de Summa, Nicolò Bizzarri, Salvatore Annunziata, Gian Franco Zannoni, Lioe-Fee de Geus-Oei, Gabriella Ferrandina, Maria Antonietta Gambacorta, Giovanni Scambia, Ronald Boellaard, Evis Sala, Vittoria Rufini, Floris HP van Velden
Visual Abstract
-
High-Temporal-Resolution Kinetic Modeling of Lung Tumors with Dual-Blood Input Function Using Total-Body Dynamic PET J Nucl. Med. (IF 9.3) Pub Date : 2024-03-28 Yiran Wang, Yasser G. Abdelhafez, Benjamin A. Spencer, Rashmi Verma, Mamta Parikh, Nicholas Stollenwerk, Lorenzo Nardo, Terry Jones, Ramsey D. Badawi, Simon R. Cherry, Guobao Wang
Visual Abstract
-
Quantitative Brain Amyloid PET J Nucl. Med. (IF 9.3) Pub Date : 2024-03-21 William J. Jagust, Venkata S. Mattay, Daniel M. Krainak, Sue-Jane Wang, Lora D. Weidner, A. Alex Hofling, Hayoung Koo, Pamela Hsieh, Phillip H. Kuo, Gill Farrar, Libero Marzella
Since the development of amyloid tracers for PET imaging, there has been interest in quantifying amyloid burden in the brains of patients with Alzheimer disease. Quantitative amyloid PET imaging is poised to become a valuable approach in disease staging, theranostics, monitoring, and as an outcome measure for interventional studies. Yet, there are significant challenges and hurdles to overcome before
-
Effectiveness and Safety of Retreatment with 177Lu-DOTATATE in Patients with Progressive Neuroendocrine Tumors: A Retrospective Real-World Study in the United States J Nucl. Med. (IF 9.3) Pub Date : 2024-03-21 Delpassand, E. S., Yazdi, S. M., Ghantoji, S., Nakasato, A., Strickland, C., Nunez, R., Shafie, A., Cork, S., Byrne, C., Tang, J., Patel, J.
Visual Abstract
-
Noninvasively Deciphering the Immunosuppressive Tumor Microenvironment Using Galectin-1 PET to Inform Immunotherapy Responses J Nucl. Med. (IF 9.3) Pub Date : 2024-03-21 Ning Liu, Xiujie Yang, Chao Gao, Jianze Wang, Yuwen Zeng, Linyu Zhang, Qi Yin, Ting Zhang, Haoyi Zhou, Kui Li, Jinhong Du, Shixin Zhou, Xuyang Zhao, Hua Zhu, Zhi Yang, Zhaofei Liu
Visual Abstract
-
Preclinical Characterization of DPI-4452: A 68Ga/177Lu Theranostic Ligand for Carbonic Anhydrase IX J Nucl. Med. (IF 9.3) Pub Date : 2024-03-21 Frédéric Massière, Norbert Wiedemann, Inês Borrego, Aileen Hoehne, Frank Osterkamp, Matthias Paschke, Dirk Zboralski, Anne Schumann, Anne Bredenbeck, Franck Brichory, Antoine Attinger
Visual Abstract
-
[18F]FET PET/MRI: An Accurate Technique for Detection of Small Functional Pituitary Tumors J Nucl. Med. (IF 9.3) Pub Date : 2024-03-21 Ilanah J. Pruis, Frederik A. Verburg, Rutger K. Balvers, Anita A. Harteveld, Richard A. Feelders, Meike W. Vernooij, Marion Smits, Sebastian J.C.M.M. Neggers, Sophie E.M. Veldhuijzen van Zanten
Visual Abstract
-
Impact of 18F-FDG PET Intensity Normalization on Radiomic Features of Oropharyngeal Squamous Cell Carcinomas and Machine Learning–Generated Biomarkers J Nucl. Med. (IF 9.3) Pub Date : 2024-03-21 Stefan P. Haider, Tal Zeevi, Kariem Sharaf, Moritz Gross, Amit Mahajan, Benjamin H. Kann, Benjamin L. Judson, Manju L. Prasad, Barbara Burtness, Mariam Aboian, Martin Canis, Christoph A. Reichel, Philipp Baumeister, Seyedmehdi Payabvash
Visual Abstract
-
18F-BMS-986229 PET to Assess Programmed-Death Ligand 1 Status in Gastroesophageal Cancer J Nucl. Med. (IF 9.3) Pub Date : 2024-03-21 Samuel L. Cytryn, Neeta Pandit-Taskar, Melissa A. Lumish, Steven B. Maron, Ping Gu, Geoffrey Y. Ku, Joanne F. Chou, Marinela Capanu, Ariel Antoine, Diane Loegel, Lara Feder, Steven Philemond, Serge K. Lyashchenko, Jason S. Lewis, Viktoriya Paroder, Amitabh Srivastava, Laura H. Tang, Heiko Schoder, Yelena Y. Janjigian
Visual Abstract
-
Efficacy of [67Cu]Cu-EB-TATE Theranostic Against Somatostatin Receptor Subtype-2-Positive Neuroendocrine Tumors J Nucl. Med. (IF 9.3) Pub Date : 2024-03-14 Njotu, F. N., Ketchemen, J. P., Tikum, A. F., Babeker, H., Gray, B. D., Pak, K. Y., Uppalapati, M., Fonge, H.
Visual Abstract
-
Interrogating the Theranostic Capacity of a MUC16-Targeted Antibody for Ovarian Cancer J Nucl. Med. (IF 9.3) Pub Date : 2024-03-14 Kyeara N. Mack, Zachary V. Samuels, Lukas M. Carter, Tara D. Viray, Komal Mandleywala, Cory L. Brooks, Michael A. Hollingsworth, Prakash Radhakrishnan, Jason S. Lewis
Visual Abstract
-
The Value of 68Ga-PSMA PET/MRI for Classifying Patients with PI-RADS 3 Lesions on Multiparametric MRI: A Prospective Single-Center Study J Nucl. Med. (IF 9.3) Pub Date : 2024-03-14 Jingyan Shi, Danyan Li, Mengxia Chen, Yao Fu, Shan Peng, Qing Zhang, Jing Liang, Qun Lu, Jiaming Lu, Shuyue Ai, Feng Wang, Xuefeng Qiu, Hongqian Guo
Visual Abstract
-
Real-World Experience with 177Lu-PSMA-617 Radioligand Therapy After Food and Drug Administration Approval J Nucl. Med. (IF 9.3) Pub Date : 2024-03-14 Abuzar Moradi Tuchayi, Surekha Yadav, Fei Jiang, Sarasa T. Kim, Rachelle K. Saelee, Amanda Morley, Roxanna Juarez, Courtney Lawhn-Heath, Yingbing Wang, Ivan de Kouchkovsky, Thomas A. Hope
Visual Abstract
-
Strong Correlation Between SUVmax on PSMA PET/CT and Numeric Drop-In γ-Probe Signal for Intraoperative Identification of Prostate Cancer Lesions J Nucl. Med. (IF 9.3) Pub Date : 2024-03-14 Anne-Claire Berrens, Malou A. Sorbi, Maarten L. Donswijk, Hilda A. de Barros, Samaneh Azargoshasb, Matthias N. van Oosterom, Daphne D.D. Rietbergen, Elise M. Bekers, Henk G. van der Poel, Fijs W.B. van Leeuwen, Pim J. van Leeuwen
Visual Abstract